The Cincinnati Children’s Center has expanded its capacity to manufacture cellular products for rare diseases.

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more ...

Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...

Cincinnati Children’s celebrated Nov. 17 the opening of a new state-of-art facility for its Applied Gene and Cell Therapy Center, which will enable the health system to increase clinical trials of ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...